A compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 do not need to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.
A compromise is reached about COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 need not seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.
A compromise is reached regardingaCOVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 donotneed to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.